An award-winning clinic specialising in cognitive impairment, including Alzheimer’s disease and dementia, has stressed the importance of clinical trials in the attempt to slow and halt the progression of the disease in the future.
Re:Cognition Health clinics, based across the south and south west of the UK, is providing education, advice and access to what it calls ‘the most advanced treatments available worldwide’.
The clinic says results from its trials of treatments for Alzheimer’s disease and other causes of mild cognitive impairment have been encouraging, offering patients participating in clinical trials the next generation of emerging medications, free of charge, before they are licensed for global use.
Participants are cared for throughout the process and monitored regularly by a study team of cognitive experts, with all medical costs covered by the pharmaceutical company providing the treatment.
Dr Emer MacSweeney, CEO and Medical Director of Re:Cognition Health said: “With the introduction of new biomarkers to detect evidence of Alzheimer’s disease at its earliest stage, there is reason for cautious optimism that new generation medications will delay progression of disease and/or boost cognition.”
Peter Brabner, whose wife Helen was diagnosed with Alzheimer’s disease at the age of 73, is supporting her through the clinical study said: “If someone has a diagnosis of Alzheimer’s disease I would say get in touch with Re:Cognition Health: they are doing excellent work and look after you so well throughout the process. We are realistic that we may not find a cure in Helen’s lifetime, but we are hoping to help other people in some way. Also, by doing something positive and pro-active about it is good for us both.”